Search
dostarlimab-gxly (JEMPERLI)
Indications:
- treatment of adult patients with mismatch repair deficient recurrent or advanced endometrial cancer* that has progressed after cisplatin-based therapy
* determined by FDA-approved test
Contraindications:
- pregnancy
Dosage:
- 500 mg every 3 weeks (4 doses)
- thereafter 1000 mg every 6 weeks
- administer as IV infusion over 30 minutes
* Injection: 500 mg/10 mL in single dose vial
Adverse effects:
- most common > 20%
- fatigue/asthenia, nausea, diarrhea, anemia, constipation
- immune-mediated reactions
- immune-mediated pneumonitis
- immune-mediated colitis
- immune-mediated hepatitis
- immune-mediated endocrinopathies
- immune-mediated nephritis
- immune-mediated dermatologic adverse reactions
- infusion-related reactions
- complications of allogeneic hematopoietic stem cell transplantation
- embryo-fetal toxicity
Mechanism of action:
- programmed death receptor-1 (PD-1)-blocking monoclonal antibody
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
JEMPERLI (dostarlimab-gxly) injection, for intravenous use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf